

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Canceled).

2 (Currently amended): The method according to ~~claim 1~~ claim 6, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

3 (Original): The method according to claim 2, wherein the aromatase inhibitor is letrozole.

Claims 4 - 5 (Canceled).

6 (Previously presented): A method of treating breast cancer by providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor.

Claims 7 - 24 (Canceled).

25 (Currently amended): A method of treating ~~a neoplasm~~ breast cancer in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination consisting of CCI-779 and an aromatase inhibitor, wherein either CCI-779, the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

26 (Original): The method according to claim 25 in which CCI-779 is provided in a subtherapeutically effective amount.

27 (Original): The method according to claim 25 in which the aromatase inhibitor is provided in a subtherapeutically effective amount.

28 (Original): The method according to claim 25 in which both CCI-779 and the aromatase inhibitor are provided in subtherapeutically effective amounts.

29 (Original): The method according to claim 25, wherein the aromatase inhibitor is letrozole.

30 (Original): An antineoplastic combination comprising an antineoplastic effective amount of a combination of CCI-779 and an aromatase inhibitor.

31 (Currently amended): A method of treating ~~a neoplasm~~ breast cancer in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination consisting of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

32 (Canceled).

33 (Currently amended): The method according to ~~claim 32~~ claim 31, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

34 (Original): The method according to claim 33, wherein the aromatase inhibitor is letrozole.

Claims 35 - 36 (Canceled).

37 (Currently amended): The method according to ~~claim 32~~ claim 31, wherein the CCI-779 or the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

Claims 38 – 44 (Cancelled).

45 (Currently amended): A pharmaceutical composition useful in treating ~~a neoplasm~~ breast cancer in a mammal in need thereof, the composition consisting of (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase inhibitor, excipients and/or a pharmaceutically acceptable carrier.

46 (Original): The pharmaceutical composition according to claim 45, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

47 (Original): The pharmaceutical composition according to claim 46, wherein the aromatase inhibitor is letrozole.

48 (Previously presented): An antineoplastic combination comprising an antineoplastic effective amount of a combination consisting of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

49 (Canceled).